Management of Intracranial Pressure in Acute Liver Failure
The most recent high-quality guideline (2023) recommends using hypertonic saline in critically ill ALF patients at risk of developing intracranial hypertension, while suggesting against routine invasive ICP monitoring and routine moderate hypothermia. 1
Primary Recommended Strategy: Hypertonic Saline
The 2023 Critical Care Medicine guidelines provide a conditional recommendation (low quality evidence) for hypertonic saline as the preferred pharmacologic intervention for patients at risk of intracranial hypertension 1. This represents the most current guidance and supersedes older recommendations.
Additional Pharmacologic Options
While the evidence base is limited, the following interventions may be considered:
- Mannitol (intravenous): Evaluated in RCTs but showed no statistically significant mortality benefit 2
- Plasma exchange: Conditional recommendation when available, particularly for hyperammonemia management 1
What NOT to Do
Avoid routine invasive intracranial pressure monitoring in ALF patients with advanced-grade encephalopathy (conditional recommendation, very low quality evidence) 1. The 2017 AGA guidelines similarly recommend against empiric ICP-lowering treatments 2.
The rationale is compelling: invasive monitoring carries hemorrhagic risk in coagulopathic patients, and the incidence of intracranial hypertension has declined dramatically—from 13% in 2009 to 3% in 2018 3. More importantly, reduced use of invasive monitoring was not associated with worse outcomes 3.
Do not routinely use induced moderate hypothermia (<34°C) for patients at risk of intracranial hypertension (conditional recommendation, very low quality evidence) 1. While older data from 2009 suggested hypothermia could bridge patients to transplant 4, the most recent guidelines advise against routine use, likely due to infection risk, cardiac dysrhythmias, and bleeding complications.
Risk Stratification: Who Needs Intervention?
Peak arterial ammonia concentration is the strongest predictor of both intracranial hypertension and cerebral death 3. Monitor ammonia levels closely to identify high-risk patients requiring preventive measures.
Patients with hyperacute liver failure (especially acetaminophen overdose) and rapidly progressive disease remain at highest risk 4.
Alternative Monitoring Approaches
Since invasive monitoring is not recommended, consider:
- Transcranial Doppler as a noninvasive alternative 5
- Clinical assessment of encephalopathy grade
- Serial ammonia monitoring 3
Adjunctive Renal Replacement Therapy
Early initiation of renal replacement therapy (RRT) serves dual purposes: managing acute kidney injury (common in ALF) and clearing ammonia, which indirectly reduces ICP 6, 5. This represents an important supportive measure even when formal ICP monitoring is not used.
Critical Pitfall to Avoid
The 2017 AGA guidelines explicitly state: "If therapy is ineffective, monitoring in the first place would be inadvisable" 2. Since five RCTs involving 410 ALF patients showed no overall effect of ICP treatment on mortality with any individual therapy (hypothermia, hypertonic saline, L-ornithine L-aspartate, mannitol, or hyperventilation) 2, the emphasis has shifted toward early preventive measures rather than reactive monitoring and treatment.
Practical Algorithm
- Identify high-risk patients: Monitor ammonia levels, assess for hyperacute presentation
- Initiate hypertonic saline in at-risk patients 1
- Start early RRT if acute kidney injury develops or ammonia remains elevated 6, 5
- Consider plasma exchange when available for severe hyperammonemia 1
- Avoid routine invasive ICP monitoring 1
- Use noninvasive monitoring (transcranial Doppler, clinical assessment) 5
- Optimize for liver transplantation as definitive treatment
This strategy reflects the evolution in ALF management where improved supportive care has reduced ICH incidence, making aggressive invasive monitoring less necessary and potentially more harmful than beneficial.